Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Eye Therapies LLC has 3 pending office actions currently active within the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 2 distinct examiners and are situated within 2 distinct art units. Mina Haghighatian serves as the busiest examiner for the portfolio, holding 2 pending office actions. This concentration shows that a majority of the company's current prosecution work is handled by a single individual, despite the involvement of multiple examiners.
The allocation of 3 pending office actions across 2 distinct art units indicates a relatively focused technological scope within the biotechnology sector. Because Mina Haghighatian manages 2 pending office actions, her specific examination style will have a significant impact on the overall prosecution results. The remaining action is handled by a second examiner, introducing some variety into the prosecution experience. Practitioners should focus on the specific trends associated with Mina Haghighatian while also accounting for the practices of the 2 distinct art units involved. This structure suggests a strategy that is largely centralized but maintains some breadth across different examination groups.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 2 | 46.1% | +39.3% |
| MERCIER, MELISSA S | 1 | 72.1% | +5.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17389556 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE THEREOF | MERCIER, MELISSA S | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17699405 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | HAGHIGHATIAN, MINA | 267d overdue |
| 17405773 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | HAGHIGHATIAN, MINA | 267d overdue |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17699405 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | HAGHIGHATIAN, MINA | 1616 | §103 | Final Rejection | 267d overdue | Pending | Mar 21, 2022 |
| 17405773 | LOW-DOSE BRIMONIDINE COMBINATIONS AND USES THEREOF | HAGHIGHATIAN, MINA | 1616 | §103 | Final Rejection | 267d overdue | Pending | Aug 18, 2021 |
| 17389556 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE THEREOF | MERCIER, MELISSA S | 1615 | §103§112 | Non-Final OA | 56d | Pending | Jul 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial